Bioethics News

Soon Printing a Human Heart on Demand Will No Longer Be Sci-Fi

January 25, 2017

(CNBC) – Imagine being able to grow a liver in a laboratory from cells and tissue for a transplant patient. Or engineering cells to grow into a heart valve to replace one damaged from heart disease. Around the world, start-ups — like Tokyo-based Cyfuse Biomedical — are emerging to develop such breakthroughs in the field of regenerative medicine. It is a market projected to reach $101.3 billion by 2022. Unlike conventional medicines and treatments, regenerative medicines have the ability to restore or heal the body’s own cells or create new body parts from a patient’s own cells and tissues, thereby eliminating tissue rejection and the excessively long wait for a donor organ.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.